FUNDAMENTALS · Fundamentals · US Healthcare

Intellia Therapeutics (NTLA) Fundamentals 2026 — Revenue Analysis | SniperIQ

Intellia Therapeutics (NTLA) is a US-listed Healthcare company in Biotechnology with a market capitalization of

.3B, trading at
1.14 on the NASDAQ. This SniperIQ fundamentals page covers Intellia Therapeutics's valuation, profitability (net margin -597.0%), revenue ($68M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
.3B
Net Margin-597.0%
Revenue (FY25)$68M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Intellia Therapeutics's market cap?

Intellia Therapeutics (NTLA) has a market capitalization of approximately

.3B, trading at
1.14 on the NASDAQ. Market cap moves with the live share price.

What is Intellia Therapeutics's P/E ratio?

Intellia Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Intellia Therapeutics?

Intellia Therapeutics runs a net profit margin of -597.0%, a gross margin of -153.7%, and an operating margin of -636.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Intellia Therapeutics generate?

Intellia Therapeutics reported revenue of $68M for fiscal year 2025, with net income of -$413M and earnings per share (EPS) of -3.81. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Intellia Therapeutics pay a dividend?

Intellia Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Intellia Therapeutics financially healthy?

Intellia Therapeutics carries a debt-to-equity ratio of 0.13x and a current ratio of 6.10x, with a market beta of 1.77. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Intellia Therapeutics a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Intellia Therapeutics (NTLA) the key facts are: market cap

.3B, revenue $68M, 52-week range 7.95-28.25. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Intellia Therapeutics's full fundamentals live

Get Intellia Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Kestra Medical Technologies (KMTS) fundamentals · Azenta (AZTA) fundamentals · CONMED (CNMD) fundamentals · Alphatec Holdings (ATEC) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons